Trial Profile
A Phase II Study of AUY922, a Novel HSP Inhibitor, in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) Failed to or Intolerance of Imatinib and Sunitinib Therapy
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Luminespib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- 16 Sep 2013 Planned end date changed from 1 Jul 2019 to 1 Oct 2019 as reported by ClinicalTrials.gov.
- 12 Jul 2011 New trial record